KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Assets (2016 - 2026)

NovoCure's Current Assets history spans 13 years, with the latest figure at $631.7 million for Q1 2026.

  • On a quarterly basis, Current Assets fell 42.01% to $631.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $631.7 million, a 42.01% decrease, with the full-year FY2025 number at $646.7 million, down 41.56% from a year prior.
  • Current Assets hit $631.7 million in Q1 2026 for NovoCure, down from $646.7 million in the prior quarter.
  • Over the last five years, Current Assets for NVCR hit a ceiling of $1.2 billion in Q3 2025 and a floor of $631.7 million in Q1 2026.
  • Historically, Current Assets has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2023.
  • Biggest five-year swings in Current Assets: grew 9.55% in 2025 and later crashed 42.01% in 2026.
  • Tracing NVCR's Current Assets over 5 years: stood at $1.1 billion in 2022, then dropped by 6.94% to $1.0 billion in 2023, then grew by 6.98% to $1.1 billion in 2024, then crashed by 41.56% to $646.7 million in 2025, then dropped by 2.33% to $631.7 million in 2026.
  • Business Quant data shows Current Assets for NVCR at $631.7 million in Q1 2026, $646.7 million in Q4 2025, and $1.2 billion in Q3 2025.